-
Postgraduate Medical Journal Sep 1978A patient with the syndrome of inappropriate antidiuretic hormone release (SIADH) following head injury and meningitis was studied during treatment with demeclocycline,...
A patient with the syndrome of inappropriate antidiuretic hormone release (SIADH) following head injury and meningitis was studied during treatment with demeclocycline, a drug known to produce a reversible nephrogenic diabetes insipidus. No changes were observed during six days of demeclocycline 1200 mg/24 hr but urine output increased significantly, with the production of a dilute urine, when the dose was increased to 2400 mg/24 hr. The patient lost weight, and all biochemical features of the syndrome were rapidly corrected despite an unchanged fluid intake and despite the persistence of high plasma levels of ADH. The rise in serum sodium was accompanied by mild sodium retention, as measured by external balance and exchangeable sodium. A complication of treatment was the development of acute renal failure possibly induced by a nephrotoxic effect of high circulating levels of demeclocyline. On stopping demeclocyline renal function returned to normal and, after some delay, SIADH returned, and was still present 9 months after initial presentation. This confirms earlier reports of the efficacy of demeclocycline in SIADH; but the authors advise caution against increasing the dose above 1200 mg/24 hr.
Topics: Demeclocycline; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Sodium; Time Factors; Vasopressins
PubMed: 103083
DOI: 10.1136/pgmj.54.635.623 -
Thorax Jun 1979Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg...
Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (greater than 135 mmol/l) in all patients after a mean of 8.6 days (SD +/- 5.3 days). Blood urea rose significantly from the pretreatment level of 4.2 +/- 2.3 mmol/l to 10.1 +/- 5.1 mmol/l at ten days (P less than 0.001). The average maximum blood urea was 13.4 +/- 6.8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of thie rise. The azotaemia could be attributed to a combination of increased urea producation and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent.
Topics: Adult; Aged; Creatinine; Demeclocycline; Female; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Sodium; Urea; Uremia
PubMed: 113900
DOI: 10.1136/thx.34.3.324 -
The American Journal of Psychiatry Jun 1982Demeclocycline, a competitive inhibitor of antidiuretic hormone at renal tubules, was studied in a patient with the syndrome of psychosis, psychogenic polydipsia, and...
Demeclocycline, a competitive inhibitor of antidiuretic hormone at renal tubules, was studied in a patient with the syndrome of psychosis, psychogenic polydipsia, and episodic water intoxication. Under double-blind, placebo-controlled conditions, demeclocycline substantially reduced the severity and frequency of hyponatremic episodes.
Topics: Adult; Demeclocycline; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Schizophrenia; Schizophrenic Psychology; Water Intoxication
PubMed: 6805340
DOI: 10.1176/ajp.139.6.828 -
JAMA Feb 1978
Topics: Aged; Ascites; Demeclocycline; Female; Humans; Kidney Failure, Chronic
PubMed: 413940
DOI: No ID Found -
Investigative Ophthalmology & Visual... Jul 1989Demeclocycline, tetracycline and other tetracycline derivatives lowered intraocular pressure (IOP) in rabbits following intravitreal injection, but the onset of this... (Comparative Study)
Comparative Study
Demeclocycline, tetracycline and other tetracycline derivatives lowered intraocular pressure (IOP) in rabbits following intravitreal injection, but the onset of this effect was not evident until 1 or more days after drug administration. Of the drugs tested, demeclocycline was the most active ocular hypotensive agent. Demeclocycline caused a dose-dependent decrease in IOP. The maximum IOP decrease of approximately 12 mm Hg occurred 5 days after intravitreal administration of 0.5 mg, with the effect persisting for over a week. Demeclocycline did not alter tonographically measured aqueous humor outflow facility or episcleral venous pressure. Based on calculated aqueous humor flow rates following 0.2 mg demeclocycline, a 62% decrease in aqueous humor formation occurred 7 days after intravitreal injection. The flow-to-diffusion ratio for ascorbate was reduced 54% 6 days after the intravitreal administration of demeclocycline, a change also consistent with suppression of aqueous humor formation. Anterior chamber aqueous humor protein concentration was increased 6 days after demeclocycline administration. No histologic changes were present in the treated eyes by light microscopy. Intravitreal demeclocycline similarly lowered IOP in cats, with the duration of effect lasting up to 20 days.
Topics: Animals; Anterior Chamber; Aqueous Humor; Cats; Demeclocycline; Injections; Intraocular Pressure; Proteins; Rabbits; Tetracyclines; Time Factors; Tonometry, Ocular; Vitreous Body
PubMed: 2501230
DOI: No ID Found -
Nordisk Medicin Aug 1969
Review
Topics: Animals; Chemical Phenomena; Chemistry; Culture Techniques; Demeclocycline; Erythromycin; Humans; L Forms; Microscopy, Electron; Mycoplasma; Mycoplasma Infections
PubMed: 4980149
DOI: No ID Found -
JAMA Jun 1980In five hyponatremic, cirrhotic patients, demeclocycline hydrochloride was used to inhibit the hydroosmotic effect of vasopressin. In four, renal impairment developed...
In five hyponatremic, cirrhotic patients, demeclocycline hydrochloride was used to inhibit the hydroosmotic effect of vasopressin. In four, renal impairment developed during the 7 to 20 days of demeclocycline hydrochloride (900 to 1,200 mg/day) administration. In these four patients, creatinine clearance fell (72 to 20 mL/min, P less than .01) as BUN (12 to 47 mg/dl, P less than .02) and serum creatinine (0.9 to 4.2 mg/dl, P less than .01) levels rose. The azotemic effect of the drug could not be accounted for consistently by volume depletion secondary to its natriuretic effect. However, a close correlation between plasma demeclocycline levels and its azotemic effect was observed. We conclude that a nephrotoxic effect of demeclocycline severly limits its usefulness in treating hyponatremia in the cirrhotic patient.
Topics: Adult; Creatinine; Demeclocycline; Glomerular Filtration Rate; Humans; Hyponatremia; Kidney; Kidney Diseases; Liver Cirrhosis, Alcoholic; Male; Natriuresis; Vasopressins
PubMed: 6770106
DOI: No ID Found -
The New England Journal of Medicine Dec 1985
Topics: Demeclocycline; Female; Humans; Hypophosphatemia, Familial; Inappropriate ADH Syndrome; Middle Aged
PubMed: 3932859
DOI: 10.1056/NEJM198512053132317 -
Annals of Internal Medicine Sep 1976
Topics: Alcoholism; Demeclocycline; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Water-Electrolyte Imbalance
PubMed: 822765
DOI: 10.7326/0003-4819-85-3-336 -
The New England Journal of Medicine Oct 1975
Topics: Carcinoma, Small Cell; Demeclocycline; Diuresis; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Syndrome; Vasopressins
PubMed: 170519
DOI: 10.1056/NEJM197510302931809